Preclinical studies have demonstrated that infiltration of tumours by various stromal cell types, including immature myeloid cells [158, 159], endothelial progenitor cells [160] or fibroblasts [141] can all mediate resistance to VEGF-targeted agents in preclinical models (Fig. 4c). Here, VEGFA is linked to neoplasm.